262 related articles for article (PubMed ID: 22110737)
1. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria.
Serghides L; Kim H; Lu Z; Kain DC; Miller C; Francis RC; Liles WC; Zapol WM; Kain KC
PLoS One; 2011; 6(11):e27714. PubMed ID: 22110737
[TBL] [Abstract][Full Text] [Related]
2. Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice.
Zanini GM; Cabrales P; Barkho W; Frangos JA; Carvalho LJ
J Neuroinflammation; 2011 Jun; 8():66. PubMed ID: 21649904
[TBL] [Abstract][Full Text] [Related]
3. S1P is associated with protection in human and experimental cerebral malaria.
Finney CA; Hawkes CA; Kain DC; Dhabangi A; Musoke C; Cserti-Gazdewich C; Oravecz T; Liles WC; Kain KC
Mol Med; 2011; 17(7-8):717-25. PubMed ID: 21556483
[TBL] [Abstract][Full Text] [Related]
4. Artesunate and erythropoietin synergistically improve the outcome of experimental cerebral malaria.
Du Y; Chen G; Zhang X; Yu C; Cao Y; Cui L
Int Immunopharmacol; 2017 Jul; 48():219-230. PubMed ID: 28531845
[TBL] [Abstract][Full Text] [Related]
5.
Elphinstone RE; Besla R; Shikatani EA; Lu Z; Hausladen A; Davies M; Robbins CS; Husain M; Stamler JS; Kain KC
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28674030
[TBL] [Abstract][Full Text] [Related]
6. Endothelial activation and dysregulation in malaria: a potential target for novel therapeutics.
Kim H; Higgins S; Liles WC; Kain KC
Curr Opin Hematol; 2011 May; 18(3):177-85. PubMed ID: 21423010
[TBL] [Abstract][Full Text] [Related]
7. Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria.
Crowley VM; Ayi K; Lu Z; Liby KT; Sporn M; Kain KC
Malar J; 2017 Nov; 16(1):463. PubMed ID: 29137631
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria.
Higgins SJ; Purcell LA; Silver KL; Tran V; Crowley V; Hawkes M; Conroy AL; Opoka RO; Hay JG; Quaggin SE; Thurston G; Liles WC; Kain KC
Sci Transl Med; 2016 Sep; 8(358):358ra128. PubMed ID: 27683553
[TBL] [Abstract][Full Text] [Related]
9. Beta interferon suppresses the development of experimental cerebral malaria.
Morrell CN; Srivastava K; Swaim A; Lee MT; Chen J; Nagineni C; Hooks JJ; Detrick B
Infect Immun; 2011 Apr; 79(4):1750-8. PubMed ID: 21245265
[TBL] [Abstract][Full Text] [Related]
10. Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria.
Miranda AS; Brant F; Rocha NP; Cisalpino D; Rodrigues DH; Souza DG; Machado FS; Rachid MA; Teixeira AL; Campos AC
Malar J; 2013 Nov; 12():388. PubMed ID: 24180288
[TBL] [Abstract][Full Text] [Related]
11. RNA-seq-based transcriptome analysis of the anti-inflammatory effect of artesunate in the early treatment of the mouse cerebral malaria model.
Wang Q; Tang Y; Pan Z; Yuan Y; Zou Y; Zhang H; Guo X; Guo W; Huang X; Wu Z; Li C; Xu Q; Song J; Deng C
Mol Omics; 2022 Sep; 18(8):716-730. PubMed ID: 35960011
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.
Wilson NO; Solomon W; Anderson L; Patrickson J; Pitts S; Bond V; Liu M; Stiles JK
PLoS One; 2013; 8(4):e60898. PubMed ID: 23630573
[TBL] [Abstract][Full Text] [Related]
13. Lipoxin A4 attenuates endothelial dysfunction during experimental cerebral malaria.
Souza MC; Pádua TA; Torres ND; Souza Costa MF; Candéa AP; Maramaldo T; Seito LN; Penido C; Estato V; Antunes B; Silva L; Pinheiro AA; Caruso-Neves C; Tibiriçá E; Carvalho L; Henriques MG
Int Immunopharmacol; 2015 Feb; 24(2):400-407. PubMed ID: 25576659
[TBL] [Abstract][Full Text] [Related]
14. Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria.
Orjuela-Sánchez P; Ong PK; Zanini GM; Melchior B; Martins YC; Meays D; Frangos JA; Carvalho LJ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5462-71. PubMed ID: 23979751
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Odhiambo OC; Wamakima HN; Magoma GN; Kirira PG; Malala BJ; Kimani FT; Muregi FW
Malar J; 2017 Jul; 16(1):268. PubMed ID: 28673299
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.
Hawkes M; Opoka RO; Namasopo S; Miller C; Conroy AL; Serghides L; Kim H; Thampi N; Liles WC; John CC; Kain KC
Med Hypotheses; 2011 Sep; 77(3):437-44. PubMed ID: 21745716
[TBL] [Abstract][Full Text] [Related]
17. Artesunate-erythropoietin combination for murine cerebral malaria treatment.
Bienvenu AL; Ferrandiz J; Kaiser K; Latour C; Picot S
Acta Trop; 2008 May; 106(2):104-8. PubMed ID: 18359468
[TBL] [Abstract][Full Text] [Related]
18. Fenozyme Protects the Integrity of the Blood-Brain Barrier against Experimental Cerebral Malaria.
Zhao S; Duan H; Yang Y; Yan X; Fan K
Nano Lett; 2019 Dec; 19(12):8887-8895. PubMed ID: 31671939
[TBL] [Abstract][Full Text] [Related]
19. Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial.
Hawkes MT; Conroy AL; Opoka RO; Hermann L; Thorpe KE; McDonald C; Kim H; Higgins S; Namasopo S; John C; Miller C; Liles WC; Kain KC
Malar J; 2015 Oct; 14():421. PubMed ID: 26510464
[TBL] [Abstract][Full Text] [Related]
20. Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria.
Moradin N; Torre S; Gauthier S; Tam M; Hawari J; Vandercruyssen K; De Spiegeleer B; Fortin A; Stevenson MM; Gros P
Malar J; 2016 May; 15(1):260. PubMed ID: 27150250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
